Posted by Michael Wonder on 11 Jun 2018
The EU approves Tagrisso for first-line treatment of EGFR-mutated non-small cell lung cancer
8 June 2018 - First-line Tagrisso offers a potential new standard of care.
Today the European Commission has granted marketing authorisation for Tagrisso (osimertinib) as monotherapy for the first-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor mutations.
The approval is based on results from the Phase III FLAURA trial published in the New England Journal of Medicine.
